title: Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
abstract: Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-based polychemotherapy followed by consolidation with high-dose therapy and autologous stem cell transplant in responding patients has demonstrated good feasibility with low toxicity in prospective studies and is widely used in eligible patients. In relapsed and refractory patients, who are not candidates for transplant approaches, therapeutic options are limited and are usually palliative. Several new agents are currently under investigation to improve the outcome of PTCL in the first line and salvage settings. Belinostat, a histone deacetylase (HDAC) inhibitor, has demonstrated broad antineoplastic activity in preclinical studies, and promising results in advanced relapsed/refractory lymphomas.Here, we report the case of a 73 year old patient with heavily pre-treated refractory PTCL in complete remission with belinostat for 39 months.
authors.affiliation: Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Pattbergstr, 1-3, Essen 45239, Germany. p.reimer@kliniken-essen-sued.de.
authors.forename: Peter
authors.initials: P
authors.lastname: Reimer
authors.forename: Shanta
authors.initials: S
authors.lastname: Chawla
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D011379:Prognosis; D012074:Remission Induction; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat
references.citation: Ai Zheng. 2004 Nov;23(11 Suppl):1443-7
references.pmid: 15566653
references.citation: Blood. 1999 Jun 1;93(11):3913-21
references.pmid: 10339500
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references.pmid: 18626005
references.citation: Blood. 1999 Apr 15;93(8):2697-706
references.pmid: 10194450
references.citation: Ann Oncol. 1997 Jun;8(6):583-92
references.pmid: 9261528
references.citation: Blood. 1997 Jun 1;89(11):3909-18
references.pmid: 9166827
references.citation: Eur J Cancer. 2002 Jan;38(1):75-81
references.pmid: 11750843
references.citation: Ann Oncol. 2002 Jan;13(1):140-9
references.pmid: 11863096
references.citation: Ann Oncol. 1990;1(1):45-50
references.pmid: 1706610
references.citation: Ann Oncol. 1998 Aug;9(8):849-55
references.pmid: 9789607